X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercepharma.com/pharma/dermavant-shows-data-bolstering-vtamas-case-approval-eczema
https://www.fiercepharma.com/pharma/fresh-threat-incytes-opzelura-dermavants-vtama-cream-hits-goal-eczema-phase-3-study
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://www.globenewswire.com/news-release/2022/08/15/2498069/34323/en/Roivant-Sciences-Reports-Financial-Results-for-the-First-Quarter-Ended-June-30-2022-and-Provides-Business-Update.html
https://www.businesswire.com/news/home/20220721005175/en/Innovaderm-Shines-as-Key-Partner-in-Clinical-Development-and-Study-Management-of-Newly-FDA-Approved-Psoriasis-Drug-Tapinarof
https://www.globenewswire.com/news-release/2022/05/24/2449068/34323/en/FDA-Approves-Dermavant-s-VTAMA-tapinarof-cream-1-for-the-Treatment-of-Plaque-Psoriasis-in-Adults-First-Topical-Novel-Chemical-Entity-Launched-for-Psoriasis-in-the-U-S-in-25-Years.html
https://www.fiercepharma.com/pharma/despite-strong-efficacy-dermatologist-survey-indicates-incyte-s-opzelura-may-have-difficulty
https://www.businesswire.com/news/home/20210311005031/en/Dermavant-Announces-Tapinarof-Data-Presentation-at-the-Innovations-in-Dermatology-Conference
https://www.businesswire.com/news/home/20201022005406/en/Dermavant-Announces-Presentation-of-Tapinarof-Pivotal-Phase-3-PSOARING-Data-at-Fall-Clinical-Dermatology-Conference
https://www.dermavant.com/dermavant-announces-publication-in-jaad-of-secondary-efficacy-and-patient-reported-outcomes-in-phase-2b-clinical-trial-of-tapinarof-cream/
https://endpts.com/vivek-ramaswamy-bags-100m-in-risk-capital-to-back-his-latest-phiii-gamble-at-dermavant/
https://www.fiercebiotech.com/biotech/roivant-appoints-nea-partner-frank-torti-as-overseer-its-vant-subsidiaries
Market Place
Share 
